MGNX MacroGenics, Inc.
Mergers ·
Bora Pharmaceuticals and Bora Biologics USA paid $122.5 million, before transaction fees and expenses, for MacroGenics' GMP manufacturing operations. The sale closed effective June 30, 2026 and is subject to post-closing adjustments.
Bora Pharmaceuticals took over MacroGenics' Rockville manufacturing site and hired about 140 former employees. The $122.5 million price is before fees, and the 8-K says extra post-closing payments may not be earned or received.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. It uses antibody-drug conjugates (ADCs) and multi-specific antibodies, which it calls DART and TRIDENT molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, and two ADCs, MGC026 and MGC028, targeting B7-H3 and ADAM9. An FDA partial clinical hold now stops new enrollment in the LINNET study of lorigerlimab in platinum-resistant ovarian cancer, following safety events in four patients. Existing study participants may continue to receive study drug. MacroGenics also operates a commercial-scale cGMP antibody manufacturing facility in Maryland and provides contract development and manufacturing services. Partnered work includes MGD024, a CD123 and CD3 bispecific developed with Gilead Sciences, Inc. The company says its collaborations have provided over $1.6 billion of non-dilutive funding since its inception in 2000.
| Product or program | What it is | Stage |
|---|---|---|
| Lorigerlimab | Bispecific DART molecule targeting PD-1 and CTLA-4 | clinical; LINNET study on partial clinical hold |
| MGC026 | B7-H3-targeting ADC with a novel TOP1i-based linker-payload | Phase 1 dose expansion, ongoing |
| MGC028 | First-in-class ADAM9-targeting ADC | Phase 1 dose escalation |
| MGC030 | Preclinical ADC targeting an undisclosed antigen | preclinical |
| ZYNYZ (retifanlimab-dlwr) | Anti-PD-1 monoclonal antibody that the company out-licensed | approved by the FDA |
| TZIELD (teplizumab-mzwv) | Anti-CD3 monoclonal antibody that the company sold to a partner | approved by the FDA |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $149.5 million | $150.0 million |
| Research and development | $147.2 million | $177.2 million |
| Net income (loss) | -$74.6 million | -$67.0 million |
| Cash from operations | -$81.0 million | -$68.4 million |
| Cash and equivalents | $57.2 million | $182.8 million |
MacroGenics, Inc. trades under the ticker MGNX on NASDAQ.
MacroGenics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:M55; LS:A1W6ND; LSX:A1W6ND.
The SEC Central Index Key (CIK) for MacroGenics, Inc. is 1125345. Its filings are on SEC EDGAR.
63,700,187 shares as of 2026-08-08, per the cover page of its 10-Q filed 2026-08-14.
Our directory records MacroGenics, Inc. under United States.
Our directory classifies MacroGenics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MacroGenics, Inc. is US5560991094.
aibio.space lists MacroGenics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. It uses antibody-drug conjugates (ADCs) and multi-specific antibodies, which it calls DART and TRIDENT molecules.
Lorigerlimab: Bispecific DART molecule targeting PD-1 and CTLA-4 Stage: clinical; LINNET study on partial clinical hold.
MGC026: B7-H3-targeting ADC with a novel TOP1i-based linker-payload Stage: Phase 1 dose expansion, ongoing.
$149.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
MacroGenics, Inc. reported a net loss of $74.6 million for the fiscal year ended Dec 31, 2025, and used $81.0 million of cash in operations, per its annual report to the SEC.
$147.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio